FAIL OFTEN, FAIL BIG, AND FAIL FAST? LEARNING FROM SMALL FAILURES AND R&D PERFORMANCE IN THE PHARMACEUTICAL INDUSTRY

RAJAT KHANNA
Tulane University

ISIN GULER
Sabanci University

ATUL NERKAR
University of North Carolina at Chapel Hill

Do firms learn from their failed innovation attempts? Answering this question is important because failure is an integral part of exploratory learning. In this study, we consider whether and under what circumstances firms learn from their small failures in experimentation. Building on organizational learning literature, we examine the conditions under which prior failures influence firms’ R&D output, in terms of amount and quality. Our empirical analysis of voluntary patent expirations (i.e., patents that firms give up by not paying renewal fees) in 97 pharmaceutical firms between 1980 and 2002 shows that the number, importance, and timing of small failures are associated with a decrease in R&D output (patent count) but an increase in the quality of the R&D output (forward citations to patents). Exploratory interviews further suggest that the results are driven by a multilevel learning process from failures in pharmaceutical R&D. Our findings contribute to the organizational learning literature by providing a nuanced view of learning from failures in experimentation.

Failure is an integral part of the innovation process. Exploratory learning, a key building block of innovation, occurs through experimentation and search (March, 1991). The literature on organizational innovation emphasizes the importance of experimentation and the establishment of organizational structures and incentives that encourage it (e.g., Ahuja & Lampert, 2001; Cannon & Edmondson, 2005; Lee, Edmondson, Thomke, & Worline, 2004; Nohria & Gulati, 1996; Thomke & Kuehnen, 2002). Inevitably, most experiments fail, but common wisdom suggests that such failures provide valuable feedback for future search efforts. However, learning from failure is far from automatic, given the psychological and organizational processes that attach negative meaning to failure (see Cannon & Edmondson, 2005, for a review.) This observation has led to a large body of prescriptive advice to embrace failure as a necessary part of the innovation process (e.g., Edmondson, 2011; McGrath, 2011). For instance, IDEO, an influential design firm known as one of the most innovative in the world, has a slogan that encourages experimentation and trial-and-error learning: “Fail often in order to succeed sooner.” In spite of the central role of failure in experimentation, there is little empirical research examining whether and how firms learn from failure in innovation.

We aim to fill this gap by shedding light on learning from failure in the course of knowledge generation (March, 1991; cf. Sitkin, 1992). In particular, we ask whether and under what circumstances firms learn from their failed attempts at innovation. While prior literature provides many important insights about learning from failure (e.g., Baum & Dahlin, 2007; Haunschild & Sullivan, 2002; Hayward, 2002; Madsen & Desai, 2010; Miner, Kim, Holzinger, &
Haunschild, 1999), most of these studies focus either on catastrophic failures, such as plane or orbiter crashes (Haunschild & Sullivan, 2002; Madsen & Desai, 2010), or operational failures, such as acquisition integration problems or product defects (e.g., Haunschild & Rhee, 2004; Hayward, 2002; Henderson & Stern, 2004). Small and frequent failures arising in the natural course of experimentation are distinct from those studied in the prior literature, because failure in innovation is generally accepted as a likely, albeit unwelcome, outcome of the experimentation process. In contrast to operational failures, such as those in product safety, acquisitions, or product selection, where it is desirable to minimize the instances of failures, small failures in experimentation are often the only way to learn about causal relationships when a complete understanding of the underlying science is unavailable to boundedly rational decision makers (Fleming & Sorenson, 2004; Sitkin, 1992). Even though experimentation and failure are indispensable for innovation, learning from failed experiments in organizational contexts is far from straightforward (e.g., Eggers, 2012a). Examining if and under what conditions firms can leverage prior failures to enhance innovation performance is therefore critical to our understanding of the innovation process (Sitkin, 1992).

In this study, we focus on a particular type of failure in the context of R&D efforts in the pharmaceutical industry. Specifically, we study how failed R&D projects in the sector are associated with the subsequent R&D performance of firms. We observe firms’ voluntary patent expirations before the legally allowed 20-year period, provided by the United States Patent and Trademark Office (USPTO), as an indicator of small failures in experimentation. Since the late 1980s, firms have been required to pay maintenance fees every four years to keep their patents active. Recent empirical evidence shows that firms let a substantial fraction of their patents expire before the regular expiration date by not paying maintenance fees (Serrano, 2010). Since pharmaceutical firms have patents ranging from several hundreds to several thousands, discontinuing some patents earlier than their legally permitted expiration date may seem trivial. However, the effort and money invested in the discovery phase of each patent as well as the relative ease of renewing a patent suggest that firms make discontinuation decisions mindfully. Hence, the voluntary discontinuation of any patent is a self-admitted failure event. We ask whether and under what conditions these events create learning opportunities in R&D.

We examine how such small failures in experimentation influence an important component of innovation outcomes: R&D performance. Successful innovation entails high R&D performance, as well as competent commercialization (e.g., Fleming, 2002; Nerkar & Roberts, 2004; Schumpeter, 1934). In this study, we focus on the former step and ask how small failures influence subsequent R&D outcomes. In doing so, we distinguish between two important dimensions of R&D performance: R&D output amount (patent count) and R&D output quality (forward citations to patents). Organizational learning literature suggests a positive influence of learning on both dimensions, but most prior research on R&D either focuses on one dimension of R&D performance or combines the two into one aggregate measure. We submit that R&D output and quality are distinct outcomes, and test the influence of failures on each outcome separately in order to get a more complete picture of organizational learning following small failures.

The paper makes three important contributions. First, we contribute to the literature on learning from failure by examining small failures in exploration. Our study specifically focuses on the experimentation that underlies the concepts of search in innovation, and asks how failures in experimentation influence subsequent innovation outcomes. We extend and test ideas on learning from failures in exploration, building on prior work on intelligent failures (Sitkin, 1992) and learning from performance feedback (Greve, 2003; March & Simon, 1958). Second, we investigate conditions under which firms are more likely to learn from small failures in experimentation. Prior literature suggests that experiences differ in terms of the learning they provide (Eggers, 2012b). In particular, we focus on the timing and importance of failures as sources of learning. We argue that early failures in R&D provide better learning opportunities for firms than do failures that come later in the R&D process. We also suggest that failures of projects that are relatively more important to the firm lead to higher learning.

This study also contributes to the literature on organizational innovation by examining failed innovation attempts as a determinant of a firm’s subsequent R&D performance. While prior literature has studied many different factors that can influence R&D outcomes (e.g., Ahuja, 2000; Griliches, 1994; Henderson & Cockburn, 1994; Rothaermel & Thursby, 2007), few studies have investigated learning from prior failures as a contributing factor.
We aim to fill this gap by disentangling the impact of failed experiments on both R&D output and quality. Ultimately, we find that small failures in experimentation are important for the R&D performance of pharmaceutical firms but have opposite effects on R&D output and quality. Specifically, small failures in experimentation lead to a decrease in subsequent R&D output but an increase in the quality of R&D outcomes. We develop an understanding of this counterintuitive result through our field interviews. In particular, the distinction between idea generation and idea selection suggests a multilevel model of learning in pharmaceutical R&D.

ORGANIZATIONAL LEARNING FROM FAILURES

Early studies on organizational learning focused primarily on increasing efficiencies as a function of experience (e.g., Argote & Epple, 1990; Yelle, 1979). Recent work in this field has examined the effect of experience on such outcomes as service quality and survival rates of firms in service and banking industries (Baum & Dahlin, 2007; Baum & Ingram, 1998). Past experience also shapes the trajectory of a firm’s innovations by increasing its absorptive capacity (Cohen & Levinthal, 1990) and its competence (March, 1991; Sorensen & Stuart, 2000). Organizations primarily learn through a search process triggered by the feedback received from the environment (Greve, 2003; Levinthal & March, 1993; March, 1991).

Although a large body of literature has established that organizations learn from their experiences, relatively few studies distinguish whether the experience in question was a success or failure (see Sitkin, 1992). Failure offers firms many opportunities to learn, but learning from failure is far from guaranteed. Most organizations find it challenging to learn from failures (Cannon & Edmondson, 2005; Edmondson, 2002), due to the lack of sufficient information about the failure as well as a difficulty in agreeing on its causes (Eggers, 2012a). For instance, it is not uncommon for organizational members to interpret causes of failure in a way that is most beneficial to themselves (Baumard & Starbuck, 2005).

However, if firms can at least partially overcome these challenges, failures can be an important source of learning. Failures may lead to process improvements, increase reliability, reduce rates of future failure, and decrease failure-related costs (Baum & Dahlin, 2007; Haunschild & Sullivan, 2002; Kim & Miner, 2007; Madsen & Desai, 2010). They enhance learning by challenging the understanding of the cause-and-effect relationships, helping firms replace existing routines and knowledge with more useful and accurate ones (e.g., Haunschild & Sullivan, 2002; Henderson & Stern, 2004; March, Sproull, & Tamuz, 1991).

Moreover, failures may change the scope and direction of the organization’s search activities. Success leads decision makers to remain on the same trajectory (Audia, Locke, & Smith, 2000), restricting the breadth of search to the neighborhood of existing knowledge (March, 1981). In contrast, failure to reach aspiration levels may trigger problemistic search, causing firms to look for solutions or alternatives that can address the problem of decreased performance (Cyert & March, 1963; Greve, 2003). Failures may also provide firms with information to focus search in new directions (Wildavsky, 1988). In firms that hold a portfolio of innovations, trial-and-error learning often influences the composition of the portfolio of projects under consideration (e.g., Bower, 1970; Burgelman, 1983, 1991; Henderson & Stern, 2004).

In sum, as this brief review of the literature suggests, there is general agreement that failures are an important source of organizational learning, although few studies have specifically focused on learning from failures in the context of experimentation. In the next section, we describe our empirical context. We then go on to develop and test our hypotheses about small failures in experimentation and R&D outcomes in subsequent sections.

CONTEXT: PATENT FAILURES IN THE PHARMACEUTICAL INDUSTRY

Patented R&D efforts of pharmaceutical firms provide the empirical context for our study of learning from small failures in experimentation. This setting provides an interesting and appealing context for several reasons. First, the highly research-intensive nature of the pharmaceutical industry (Henderson & Cockburn, 1994) makes it suitable for examining the R&D process and outcomes. More specifically, patents have a particular strategic importance in this industry (Grabowski & Vernon, 1992; Scott Morton, 2000). Pharmaceutical research is expensive and risky. It takes up to one billion dollars to bring a new drug into the market (Grabowski, 2002; Henderson & Cockburn, 1994; PhRMA, 2007), and the lengthy nature of the clinical trial process requires pharmaceutical firms to disclose sensitive proprietary knowledge, putting them
at risk of imitation (DeCarolis, 2003; Polidoro & Toh, 2011). Pharmaceutical firms rely on patents to protect the knowledge created within the firm (Gilbert & Shapiro, 1990; Grabowski, 2002; Klemperer, 1990). Luckily, patents provide a relatively effective method of guarding proprietary intellectual property for pharmaceutical firms (Levin, Kleverick, Nelson, Winter, Gilbert, & Griliches, 1987). Pharmaceutical firms patent every innovation possible (Cohen, Nelson, & Walsh, 2000; Levin et al., 1987; Paruchuri, Nerkar, & Hambrick, 2006) and start patenting early in the research process (Penner-Hahn & Shaver, 2005). A survey-based study found that pharmaceutical firms have the highest propensity to patent their innovations, with around 80% of their innovations protected by patents, as compared to an average of 35% across all industries studied in the survey (Arundel & Kabla, 1998). Moreover, pharmaceutical firms often reward scientists on the number of patents produced (Stern, 2004), and previous research has established a positive correlation between the number of patents and profitability in science-based industries, such as pharmaceuticals (Cockburn & Griliches, 1988; Jaffe, 1986).

The second reason for choosing this context is that many patented inventions in the pharmaceutical industry end up as small failures in experimentation. Unlike other industries, such as electronics or computers, in which patents are granted for products, patents in the pharmaceutical industry are granted early in the R&D process for research ideas that may or may not become products (Lehman, 2003). As in many innovative industries, the outcomes of R&D in the pharmaceutical industry are highly skewed (Scherer & Ross, 1990). Although patented ideas have crossed the first hurdle within the firm, they have a long way before they can turn into drugs and provide returns. In fact, most patents in the pharmaceutical industry do not lead to products. Firms typically apply for patents for lead compounds before or during the preclinical trials stage (Heled, 2012; Ward, 1992). Patented compounds then go through a long process of preclinical and human trials to identify suitable drugs (PhRMA, 2007). This process involves several stages. First, scientists try to understand the disease in question, and its underlying causes, through studies of changes in genes and how these changes can lead to the disease. Second, scientists look for a “target,” an altered gene or molecule, that can interact with a potential drug. Third, scientists validate the identified target for its role in the disease and successful interaction with the drug molecule through extensive experiments. Once scientists have an understanding of the disease and the potential drug, they begin the process of finding the lead compounds that can be used to treat the disease. Fourth, after conducting preliminary safety tests and optimization studies, firms select a small number of compounds that are further tested in preclinical trials, a process that establishes the safety of drugs in animals before these drugs can be tested in humans. On average, of the 5,000–10,000 compounds tested in the fourth step, only around 250 are selected for preclinical testing (lead compounds). After extensive tests in preclinical studies, one to five lead compounds (drug candidates) are selected for further study in clinical trials. Firms file an investigational new drug (IND) application with the Food and Drug Administration to begin clinical trials in humans for these drug candidates. About one out of every five drug candidates successfully clears all three phases of clinical trials and is commercialized in the market for the treatment of the disease in question (Grabowski, 2002). In sum, failures in pharmaceutical research mirror closely the idea of small failures in experimentation in this paper and are nicely captured in the patent data (Thomke, 2003; Thomke & Kuemmerle, 2002).

We examine the impact of small failures on two distinct dimensions of R&D performance: (1) R&D output and (2) R&D quality. R&D output has been used as a measure of innovation performance in many studies, as it represents a higher rate of innovation output (e.g., Ahuja, 2000; Cockburn & Henderson, 1998; Gambardella, 1992; Rothaermel & Thursby, 2007; Somaya, Williamson, & Zhang, 2007). R&D output “represents an externally validated measure of novelty” (Griliches, 1990, quoted in Ahuja, 2000: 433) and has economic significance (Scherer & Ross, 1990). An increase in R&D output not only suggests that a firm engages in more experimentation, but also that the firm’s engagement in experimentation is likely to lead to a larger diversity of solutions, which in turn increases the probability of finding a high-quality solution (Terwiesch & Ulrich, 2009; Terwiesch & Xu, 2008). Regarding the second measure of R&D performance, unlike output in manufacturing, in which units without defect are identical, R&D output varies greatly in terms of quality (Cardinal, 2001). It is therefore important to understand whether and how prior failures influence the quality of R&D outcomes.
LEARNING FROM SMALL FAILURES IN EXPERIMENTATION

Small failures in experimentation provide opportunities for learning in multiple ways. First, frequency and scale of small failures provide firms with valuable feedback that helps shape the direction of the R&D portfolio. Firms that experience small failures on a frequent basis can form a more developed understanding of causal relationships without incurring large costs and can reallocate resources accordingly (Eggers, 2012a). Second, small failures encourage learning by initiating a search for the causes of such failures without threatening the existence of the firm or the decision makers, as larger, more visible failures may do. Since these failures do not endanger the survival of the firm, it is possible for the firm to both attend to such failures and engage in the search process. The experimental nature of these failures encourages decision makers within firms to analyze the outcomes more objectively (Baumard & Starbuck, 2005). Firms can learn from experimentation-driven failures internally before they make further investments in a particular product or innovation. 3M, one of the firms in our sample, does not favor following any master plan or engaging in complex strategic planning, but, rather, promotes a culture in which employees are not afraid to “try a lot of stuff and keep what works” (Collins & Porras, 1994: 159).

Moreover, small failures in experimentation are associated with deliberate and mindful learning processes (Levinthal & Rerup, 2006; Sitkin, 1992). When firms have an understanding of the underlying scientific principles, they can come up with innovative ideas deductively (Fleming & Sorenson, 2004). But, when the underlying science is poorly understood and uncertainty with respect to outcomes is high, the firm needs to engage in experimentation in order to innovate (Terwiesch & Ulrich, 2009). As scientists can gain a better sense of the causal relationships by testing and ruling out hypotheses, new ideas generated through experimentation will on average be of higher quality.

In addition, experimentation stimulates learning by increasing the number and variety of solutions generated, and, in turn, the quality of the final solution (Terwiesch & Ulrich, 2009; Terwiesch & Xu, 2008; Thomke, 2003). As firms actively engage in experimentation, they are likely to experience more failures, which in turn could lead to more innovative and successful outcomes (Thomke, 2003). Since such failures stimulate distant search and further experimentation, they are likely to result in a larger variability in the innovation output. Firms are then more likely to produce outliers in their innovation portfolios in terms of quality. Increasing variability enhances the likelihood of hitting “home runs” rather than producing consistently mid-range innovations in terms of impact. We therefore hypothesize that:

Hypothesis 1a. As a firm’s small failure experience increases, its subsequent R&D output will increase.

Hypothesis 1b. As a firm’s small failure experience increases, its subsequent R&D output quality will increase.

Failure of Important Projects

Small failures in experimentation may vary in terms of how important they were to the firm before the failure occurred. For instance, a failed project that has been endorsed by top management might be considered a failure of greater importance than one that was initiated by lower levels of management. In the present study, we define the importance of a small failure in terms of the project’s expected performance before it eventually failed. In other words, decision makers in the firm had more expectations from a more important project before failure. As such, these failures are likely to be more visible within the firm. In the context of pharmaceutical R&D, a project’s importance is highly related with its scientific value, or its impact on subsequent research. Note that the importance of a project is distinct from its size, which is often defined in terms of the investment at stake or consequences of failure. It is possible for a project that has required a lot of investment to generate little scientific or commercial value, just as it is possible for a small project in terms of outlays to generate high value. By definition, we focus only on small failures that are similar in the levels of investment and limited in consequences. Still, they may vary in terms of perceived potential and value.

We argue that important failures will elicit more learning for the following reasons. First, more important failures attract greater attention from decision makers within the firm. Given that managerial attention is scarce and selective, it is likely to be allocated to projects that were prominent before failure (Hoffman & Ocasio, 2001). Organizational decision makers may neglect to acknowledge failures in projects of lower importance, focusing on successful
projects instead (Cannon & Edmondson, 2005; Madsen & Desai, 2010). Managers may fail to attend to the weak cues created by failures that deemed peripheral to the firm (Eggers, 2012a; Rerup, 2009). Failures of projects of little importance are not likely to challenge decision makers’ core beliefs (Baumard & Starbuck, 2005). In contrast, failures with a higher profile elicit surprise, are recognized more easily, and lead to changes in behavior more often, consequently affecting performance (Van de Ven, 1986).

In the context of small failures in experimentation, small failures of low importance to the firm may run the risk of going unnoticed, being deliberately ignored, or being perceived at the aspiration level. In contrast, projects that were considered important to the firm before the failure trigger more extensive search for the causes and a more careful reallocation of R&D resources, which in turn is likely to improve the firm’s subsequent R&D outcomes. We therefore expect firms that experience small failures of higher importance to enjoy a subsequent increase in their R&D performance.

Hypothesis 2a. As a firm experiences small failures of higher importance, its subsequent R&D output will increase.

Hypothesis 2b. As a firm experiences small failures of higher importance, its subsequent R&D output quality will increase.

Fail Early or Fail Late?

Prior research has argued that timing of experience is an important component of learning in the context of innovation (Eggers, 2012b). The effect of the timing of failures on R&D performance, however, is relatively understudied. As discussed in the previous section, failures provide firms with information on what might be wrong, and work as feedback that can improve performance going forward. The timing of the failure is important to the firms’ learning outcomes, as it determines how quickly firms get feedback about a project. Experimental research shows that subjects who are given quick feedback will eliminate incorrect choices and learn faster. Also, efficacy of feedback diminishes with the time elapsed in providing it (Skinner, 1954). Delayed feedback may be muddled with noise, making it hard for decision makers to assess relationships between actions and outcomes (Denrell, Fang, & Levinthal, 2004). Kettle and Häubl (2010) emphasized the importance of early feedback and its positive impact on performance. Sitkin (1992) suggested that small failures lead to most learning when they elicit quick feedback, so that the firm can learn, try new solutions, and generate new feedback.

In the context of innovation, the timing of a failure refers to the point in the R&D process at which a firm faces and acknowledges the failure. For instance, in the pharmaceutical industry, a compound may fail early in development, even before preclinical trials, or many years later, during late-stage clinical trials. Whether a firm will face failure relatively early or late in the development of an innovation depends on both the external environment and internal practices. If internal practices within the firm are oriented toward identifying failures, then the likelihood of spotting failures early and learning from them will be higher than when there is no specific attention given to the process. Sometimes, firms are so constrained by the signals from the external environment that they have no choice but to wait before labeling a technology as a success or failure. Interim feedback helps firms identify potential problems and motivates them to engage in search to find solutions (Jordan & Audia, 2012). This idea also resonates with anecdotal evidence on the approach of highly innovative firms. For instance, Rich DeVaul, head of the Rapid Evaluation Team at Google declared, “Why put off failing until tomorrow or next week if you can fail now?” (Gertner, 2014)

Based on the discussion above, we expect the timing of feedback to influence R&D performance. Early feedback in the R&D process allows firms to manage available resources and limit allocation of resources to unproductive arenas. Also, early failures allow firms to experiment in more ways, compared to failures that come late in the R&D process. In contrast, when feedback comes late in the R&D process, it may be hard to pinpoint the exact decisions or actions that led to the failure, therefore confounding learning. Moreover, later failures may lead to escalation of commitment and cause a firm to continue related investments (Staw, 1976). R&D in high-tech industries is path dependent, and it is difficult for firms to change direction after significant progress has been made. A firm that receives early feedback on a technology may find it easier to reconfigure R&D investments and implement the learning from failures more effectively.

Hypothesis 3a. As a firm experiences small failures earlier in the R&D process, its subsequent R&D output will increase.

Hypothesis 3b. As a firm experiences small failures earlier in the R&D process, its subsequent R&D output quality will increase.
METHODS

We test our hypotheses with data on patent expirations in the pharmaceutical industry. We operationalize a small failure as a firm’s decision to discontinue a patent, leading to its expiration before the end of its legal life of 20 years. In the late 1980s, USPTO made it necessary for firms to pay maintenance fees every 4, 8, and 12 years to keep their patents active. Any firm or entity failing to pay the fees at the scheduled time has its patent expired. The most likely reason for early discontinuation of a patent is the lack of relative value as perceived by the firm (Serrano, 2010).

After the introduction of the maintenance fees in the Manual of Patent Examining Procedure, Chapter 2500 in 1980, pharmaceutical firms have discontinued a large number of patents, with expired patents reaching up to 50% of total patents held (Serrano, 2010). Figure 1 shows the premature expiration of patents between 1985 and 2002 for 97 pharmaceutical firms analyzed in the current study. A quick look at the figure suggests that, immediately following the introduction of patent law changes in 1980, firms discontinued only a small proportion of existing patents, but this share has increased dramatically in recent years, by between 40% and 60%. The small number of patents discontinued in the beginning is also suggestive of the critical role of firms’ decision making. In the absence of relevant information on their patents during initial years, firms did not discontinue as many patents. With time, firms have started to use patent expirations to manage their patent portfolio.

Serrano (2010)’s finding that patents that are potentially less valuable are more likely to be discontinued suggests that a firm’s decision to discontinue its patents prematurely is not random but rather deliberate in nature. As we discussed in the previous sections, patents are critical to the success of R&D in the pharmaceutical industry (Cockburn & Griliches, 1988; Jaffe, 1986). Interestingly, patent maintenance fees are negligible compared to the costs of acquiring a patent. Total fees to maintain a patent that has already been granted are less than $15,000 in total. Given the high potential value of a patent and the low maintenance fee, it is reasonable to think that firms would discontinue a patent only if they have good reason to believe that it has very limited value. In the time between the patent grant and the renewal date, the firm receives information about the future value of the patent. This information could be external (e.g., about other technological advancements) or internal (e.g., about the perceived viability of the project). Discontinuation of a patent

FIGURE 1
Number of Expired Patents for Firms Included in this Study between 1985 and 2002

<table>
<thead>
<tr>
<th>Application Year</th>
<th>Total Number of Patents</th>
<th>Total Number of Patents Expired</th>
<th>Number of Patents Expired after 4 Years</th>
<th>Number of Patents Expired after 8 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>1985</td>
<td>4500</td>
<td>500</td>
<td>700</td>
<td>200</td>
</tr>
<tr>
<td>1986</td>
<td>5000</td>
<td>550</td>
<td>800</td>
<td>250</td>
</tr>
<tr>
<td>1987</td>
<td>5500</td>
<td>600</td>
<td>900</td>
<td>300</td>
</tr>
<tr>
<td>1988</td>
<td>6000</td>
<td>650</td>
<td>1000</td>
<td>350</td>
</tr>
<tr>
<td>1989</td>
<td>6500</td>
<td>700</td>
<td>1100</td>
<td>400</td>
</tr>
<tr>
<td>1990</td>
<td>7000</td>
<td>750</td>
<td>1200</td>
<td>450</td>
</tr>
<tr>
<td>1991</td>
<td>7500</td>
<td>800</td>
<td>1300</td>
<td>500</td>
</tr>
<tr>
<td>1992</td>
<td>8000</td>
<td>850</td>
<td>1400</td>
<td>550</td>
</tr>
<tr>
<td>1993</td>
<td>8500</td>
<td>900</td>
<td>1500</td>
<td>600</td>
</tr>
<tr>
<td>1994</td>
<td>9000</td>
<td>950</td>
<td>1600</td>
<td>650</td>
</tr>
<tr>
<td>1995</td>
<td>9500</td>
<td>1000</td>
<td>1700</td>
<td>700</td>
</tr>
<tr>
<td>1996</td>
<td>10000</td>
<td>1050</td>
<td>1800</td>
<td>750</td>
</tr>
<tr>
<td>1997</td>
<td>10500</td>
<td>1100</td>
<td>1900</td>
<td>800</td>
</tr>
<tr>
<td>1998</td>
<td>11000</td>
<td>1150</td>
<td>2000</td>
<td>850</td>
</tr>
<tr>
<td>1999</td>
<td>11500</td>
<td>1200</td>
<td>2100</td>
<td>900</td>
</tr>
<tr>
<td>2000</td>
<td>12000</td>
<td>1250</td>
<td>2200</td>
<td>950</td>
</tr>
<tr>
<td>2001</td>
<td>12500</td>
<td>1300</td>
<td>2300</td>
<td>1000</td>
</tr>
<tr>
<td>2002</td>
<td>13000</td>
<td>1350</td>
<td>2400</td>
<td>1050</td>
</tr>
</tbody>
</table>

Academy of Management Journal

April
suggests that the firm has received negative feedback. The high rate of discontinuation is consistent with the fact that most patented compounds fail before introduction to the market (Grabowski, 2002). Early patenting activity represents the large number of “bets” taken by the pharmaceutical firms, while early expirations represent culling out unpromising opportunities from the research portfolio as a result of incoming information. With a reasonable understanding that the patent discontinuations represent small failure events, the uncertainty in estimating the value of a given patent in advance and availability of specific checkpoints to evaluate the fates of patents make this setting appealing for a study of learning from small failures in experimentation.

Data and Sample

We obtained the data on patent expirations from USPTO. To be consistent with previous research, we considered the 3-digit USPTO classes 514 and 424 to identify patents in pharmaceutical industry (Anand, Oriani, & Vassolo, 2010; Guler & Nerkar, 2012). These patents belonged to more than 200 firms. Since we are examining the effect of patent discontinuations on R&D outcomes, we only kept firms in our sample that were active in patenting. Therefore, we removed firms that did not patent for more than 20 years between 1980 and 2002, leading to the final sample consisting of 97 pharmaceutical firms.

Table 1 lists 30 major pharmaceutical firms out of the 97 firms in our sample. USPTO provides information on all expired patents and the stage at which patents were discontinued; that is, first stage (after 4 years from the application date), second stage (after 8 years from the application date), or third stage (after 12 years from the application date). As we propose to measure learning at the firm level, we aggregated the number of discontinued patents at the firm–year level, leading to a final panel that contains 2,015 firm–year observations. After the introduction of the maintenance fee regime in December 1980 by USPTO, the first set of patents to expire did so in 1985 (after the first deadline of 4 years), so our dataset captures every discontinued patent following the regime change. Of 156,267 patents granted to the 97 firms in our sample, 56,630 patents (36.24%) were discontinued as of 2002. We tracked all variables between 1980 and 2002 in order to capture all patents that were at risk of discontinuation in 1985, and tracked all expired patents between 1985 and 2002.

### Table 1

<table>
<thead>
<tr>
<th>Abbott</th>
<th>Bristol-Myers Squibb</th>
<th>Monsanto</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ajinomoto</td>
<td>Chiron</td>
<td>Novartis</td>
</tr>
<tr>
<td>Allergan</td>
<td>Eli Lilly</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>American Cyanamid</td>
<td>Fujisawa Pharmaceutical</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Amgen</td>
<td>Genentech</td>
<td>Pharmacia AB</td>
</tr>
<tr>
<td>Astra</td>
<td>Genzyme</td>
<td>Roche</td>
</tr>
<tr>
<td>Aventis</td>
<td>Glaxo Wellcome</td>
<td>Schering</td>
</tr>
<tr>
<td>Baxter</td>
<td>Janssen Pharmaceutical</td>
<td>Shionogi</td>
</tr>
<tr>
<td>Bayer</td>
<td>Mallinckrodt Medical</td>
<td>SmithKline Beecham</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Merck</td>
<td>Zeneca</td>
</tr>
</tbody>
</table>

1 A complete list of firms is available from authors upon request.

2 The pharmaceutical industry experienced a big wave of mergers and acquisitions (M&As) during the period of our study. In such cases, we kept the firms as separate entities before the M&A occurred and combined them in a single entity afterward.
techniques, and products, and are therefore an important indicator of innovation” (DeCarolis & Deeds, 1999, quoted in Somaya, Williamson, & Zhang, 2007: 922). There are two main issues with using patents as a proxy for innovation (Griliches, 1990). First, not all inventions are patented. This is a problem in the pharmaceutical industry, where patents provide an effective way of protecting intellectual property (Levin et al., 1987) and are therefore an important indicator of innovation (DeCarolis & Deeds, 1999; Henderson & Cockburn, 1996; Scott Morton, 2000). Second, not all patented inventions become innovations. Even so, patents have been shown to have a strong correlation with other firm-level innovation outputs, such as the number of new product introductions (Basberg, 1982; Comanor & Scherer, 1969) and sales from new products (Comanor & Scherer, 1969) as well as innovative activity (Acs & Audretsch, 1989).

It is possible that patents that contribute to R&D performance in period $t$ can become failures in periods after $t$; that is, patents that firms produce in a given period can be discontinued prematurely at a future time. Although specifications of our model take into account this endogeneity, and the model provides efficient estimates, we used only the number of patents that did not get prematurely discontinued in calculating our dependent variable.3

We measured the quality of R&D output for each firm as the total number of citations to all successful patents; that is, patents that did not get discontinued prematurely. Numerous studies have provided evidence of correlations between the importance of patents and citations to patents, and have established the use of citations as a legitimate proxy for the quality of innovative or inventive performance (Jaffe, Trajtenberg, & Henderson, 1993; Pavitt, 1988; Trajtenberg, 1990). While prior literature favors a citation-weighted measure of R&D output, we examined R&D output and quality separately in order to gain a better understanding of how learning from failure influences R&D performance. Both measures were log-transformed due to skewness.

Independent Variables

*Quantity, timing, and relative importance of small failures.* The quantity of a firm’s small failures was measured as the number of patents that were discontinued due to non-payment of maintenance fees by the firm each year between 1985 and 2002. To test our arguments related to the timing of failures, we calculated the number of discontinued patents at each stage of patent discontinuation (i.e., at 4, 8, and 12 years). On average, we expect a patent discontinued at 4 years to have elicited feedback earlier than a patent discontinued at 12 years.4 In order to measure the importance of a discontinued patent, we calculated the citations to the patent up until the year of expiration. Number of forward citations is a commonly used measure of a patent’s value and its impact on future inventions (Jaffe, Trajtenberg, & Henderson, 1993; Pavitt, 1988; Trajtenberg, 1990), and captures the expectations of decision makers about the potential of a given patent before expiration.

Control Variables

We used several control variables that could have confounding effects on R&D performance. First, we controlled for the size of firms’ R&D units, as large R&D units are likely to have higher output. We calculated the size of the R&D unit by counting the number of scientists with patent applications in each firm for every year (McFadyen & Cannella, 2004). As firms may also source innovation externally (Ahuja, 2000; Ahuja & Katila, 2001; Sampson, 2007), we controlled for the count of the alliances for each firm in our sample for each year. Geographic diversity may also affect innovation in multinational firms (MNCs) (Kobrin, 1991; Lahiri, 2010). We therefore included a count of the number of countries that were represented in the patent applications of a firm in a given year.

In this paper we are specifically interested in small failures in the form of patent expirations in the pharmaceutical industry. Some patent expirations, however, may in fact represent larger failures, such as a major failure in the firm’s research agenda, or termination of a project due to litigation. We included two controls to ensure that our sample indeed captures learning from small failures. First, we controlled for the technological focus of the firm’s discontinued patents at the firm-year level. It is possible that a large number of failures concentrated in a few technological classes in fact represent one big failure.

---

3 The conclusions are robust to using the raw patent count as a measure of R&D output.

4 While this assumption need not always be true (firms might receive early feedback and continue to maintain some patents), this noise is likely to make our results more conservative. Please see the Discussion section for a more detailed consideration of this possibility.
in the firm’s research portfolio, as opposed to many small failures. The technological focus variable was calculated with the Herfindahl index for the technological classes of each firm’s prematurely discontinued patents in any given year. The value of this index ranges from zero to one. A higher value indicates the presence of a large number of patents in a small number of technological classes, and a value close to zero indicates that the discontinued patents were from different technological classes. Second, we included the number of litigations faced by each firm in our sample to account for the possibility of larger failures in the sample. We constructed this variable using the number of lawsuits filed against each firm at both the state and federal levels in a given year, as reported in Lexis-Nexis Legal Research database.

We calculated the moving average of each control variable for the past three years to account for long-lasting effects and to smooth out sharp changes in these variables. In addition to the time-varying variables, time-invariant variables specific to the firm are taken into account using the Arellano–Bond method (described below; Arellano & Bond, 1991) via first differencing. Figure 2 provides a brief description of all variables and includes a sample data point for Abbott in 1998.

Empirical Model

The following models test the relationships between small failures and R&D performance in a panel dataset for 97 firms for a period of 22 years:

\[
P_{it} = \beta_1 P_{i,t-1} + \beta_2 F_{i,t-1} + \beta_3 C_{it} + u_{it} \quad (1)
\]

\[
Q_{it} = \beta_1 Q_{i,t-1} + \beta_2 F_{i,t-1} + \beta_3 C_{it} + v_{it} \quad (2)
\]

In Equation (1), \( P_{it} \) is R&D output, measured as the number of patents filed by firm \( i \) in year \( t \); \( P_{i,t-1} \) is the lagged value of R&D output for firm \( i \); and \( F_{i,t-1} \) is the vector of expired patent characteristics, including number, importance, and timing, for firm \( i \) in period \( t - 1 \). \( C_{it} \) is the matrix of control variables and includes size of the R&D team, number of alliances, technological focus, number of litigations, and geographical diversity. Equation (2) has the same right-hand side variables, but the dependent variable \( (Q_{it}) \) is R&D output quality, measured as citations to the

FIGURE 2
Sample Data Point for the Pharmaceutical Firm Abbott in 1998 with a Description of the Variables

- R&D output (log): log of number of patents that did not prematurely expire for a firm in a given year = 4.52
- R&D output quality (log): log of number of citations to patents that never expired for a firm in a given year = 6.27
- Number of alliances: Number of alliances made by a firm in a given year (moving average, 3 years) = 16
- R&D unit size: Number of scientists in a firm in a given year (moving average, 3 years) = 678
- Number of countries: Number of countries that were the origin of patents per firm per year (moving average, 3 years) = 4
- Technological focus: Herfindahl index for the technological classes of discontinued patents in a firm in a given year (moving average, 3 years) = 0.09
- Number of litigations: Number of lawsuits at both the state and federal level against a firm in a given year (moving average, 3 years) = 10
- Unit of Analysis: Firm-Year
  - Firm: Abbott
  - Year: 1998
- Importance of failures: Number of citations to the expired patents per firm per year = 541
- Failures (total): Total number of patents expired per firm per year = 40
- Failures after 4 years: Number of patents that expired after 4 years per firm per year = 14
- Failures after 8 years: Number of patents that expired after 8 years per firm per year = 18
- Failures after 12 years: Number of patents that expired after 12 years per firm per year = 8

Khanna, Guler, and Nerkar
Several empirical issues with Equations (1) and (2) arise in the present estimation. First, there is a possibility that small failures are endogenous to R&D performance—that is, firms choose to give up patents because they believe that they are going to produce more patents in the next period. As such, causality can run in both directions, leading to correlation between the error term (\( u_t \)) and \( v_t \) in Equations (1) and (2), respectively and independent variables (\( F_{it} \)).

Second, time-invariant fixed effects such as geography and firm culture may be correlated with the independent variables. Under such circumstances, unobserved fixed effects are combined with the error term, leading to a correlation between independent variables and the error term, a primary reason for biased coefficients. If \( Z_i \)’s are the firm-specific, time-invariant fixed effects, and \( e_{it} \) is the observation-specific error term, the error term in Equation (1) is:

\[
u_{it} = Z_i + e_{it} \tag{3}\]

Third, both Equations (1) and (2) have lagged dependent variables to account for the dynamics in the process of patenting. Adding the lagged dependent variable on the right-hand side of the equation captures the effect of what firms patented in period \( t - 1 \) on what firms patent in period \( t \), instead of incorrectly attributing it to the other explanatory variables. However, this can significantly inflate the coefficient on the lagged dependent variable and deflate coefficients on other explanatory variables (Kelly, 2002).

To deal with these issues, we used the general method of moments-based estimation introduced by Arellano and Bond (1991). The Arellano–Bond method is standard when it comes to estimating dynamic panel models where time-variant fixed effects can substantially influence the coefficients on the independent variables of interest. The Arellano–Bond method, first proposed by Holtzeakin, Newey, and Rosen (1988), uses appropriate lags of both dependent and independent variables as instruments for first-differenced dependent and explanatory variables respectively. By using previous lags as instruments, the Arellano–Bond model provides efficient estimates of parameters. Since both dependent and independent variables are first differenced, time-invariant fixed effects are subtracted out in the model. Previous research has used the Arellano–Bond model to resolve similar issues (David, Yoshikawa, Chari, & Rasheed, 2006; Knott, Posen, & Wu, 2009; Milanov & Shepherd, 2013; Uotila, Maula, Keil, & Zahra, 2009). After first differencing, Equation (1) looks like this:

\[
\Delta P_{it} = \beta_1 \Delta P_{i,t-1} + \beta_2 \Delta F_{it} + \beta_3 \Delta G_{it} + \Delta e_{it} \tag{4}\]

Since \( Z_i \) is time-invariant, it is subtracted out after differencing. As the farthest lag that appears for output is \( P_{it-2} \) in Equation (4), lags of four or higher can be used as instruments in the model.\(^5\) Analogously, lags of four or higher of endogenous variables can be used as instruments for \( \Delta F_{it-1} \). To check the validity of instruments used in the model, we performed Sargan’s test of over-identifying restrictions (Sargan, 1958). We were not able to reject the null hypothesis that over-identifying restrictions are valid (\( p \) value of \( \sim 0.8 \)), suggesting that instruments are uncorrelated with the residuals; hence, estimates from the model are not biased (Davidson & MacKinnon, 1993). In addition, after comparing Wald \( \chi^2 \) values, which are quite high for all our models, with critical values provided in Stock and Yogo (2005), we found no evidence of weak instruments in the present study. The Arellano–Bond estimator is also designed for large \( N \) and small \( T \), which makes the use of this model for the present study more relevant. The same approach is used to estimate Equation (2).

**RESULTS**

Table 2 presents the descriptive statistics and partial correlation matrix for our variables. Since both measures of R&D performance used in this study are count variables and are skewed, we used the logs\(^6\) of R&D output and R&D output quality in order to correct for the non-normality of the distribution (Chaganti & Damanpour, 1991; Ruef & Patterson, 2009). As evident from Table 2, correlations between some of the independent variables are

---

\(^5\) We do not use the first lag as an instrument in our models because we found autocorrelation of first order. If, for example, we have the term \( P_{i,t-1} \) in the model, because of first order autocorrelation, we do not use \( P_{i,t-2} \) as an instrument but instead use \( P_{i,t-3} \) and further lags as instruments.

\(^6\) Usually it is appropriate to use Poisson or negative binomial models when the dependent variable is a non-negative integer. However, as noted, the most appropriate model for our data were the Arellano–Bond model, and this model does not allow a negative binomial or Poisson specification. We therefore use a log-transformed dependent variable in our models. Sensitivity analyses with count models are reported below.
quite high. In order to ensure that multicollinearity is not an issue in our model, we estimated the variance inflation factors (VIFs). VIFs for all variables are less than 10, with an average value of 3.35 for models testing Hypothesis 1 and 2.22 for models testing Hypotheses 2 and 3. Also, as the total expired patents equals the sum of expired patents after 4, 8, and 12 years, we excluded total expired patents from the model when testing for the separate effects of expired patents after 4, 8, and 12 years.

Tables 3 and 4 present the results of the Arellano–Bond models that use the logarithm of R&D output and R&D output quality as dependent variables, respectively. Our first set of analyses uses R&D output as a measure of R&D performance. Model 1 in Table 3 is the baseline model with only controls. Models 2 and 3 include the total number of expired patents and importance of failures, respectively. The total number of expired patents in Model 3 has a significant and negative effect on output. This is contrary to Hypothesis 1a, which predicted a positive relationship between number of failures and R&D output. Models 4, 5, and 6 contain the number of expired patents after 4, 8, and 12 years, respectively. We included all independent variables except the total number of expired patents (to avoid multicollinearity) in Model 7 (full model). Hypothesis 2b, which predicted a positive relationship between the importance of failures and R&D output quality, is supported, as the coefficient on the importance of failures in Model 7 is positive and significant at $p < 0.001$. Hypothesis 3b, which predicted that early failures would increase R&D output quality more than later failures, is also supported, as the coefficient on expired patents after 4 years is positive and significant, whereas the coefficient of expired patents after 8 years is not significant, and that of expired patents after 12 years is negative and significant. R&D unit size and number of alliances have a positive effect on innovation quality. Geographic diversity has no effect. In other words, we found support for all of our hypotheses with respect to the quality measure of R&D performance, but not with respect to the output measure.

Based on calculations from Models 3 and 7 (in Tables 3 and 4), pharmaceutical firms produced 0.2% fewer patents while the quality of R&D output increased by 0.3% on average for each failure. Along the same lines, firms reduced the number of patent applications by 0.03% but increased patent quality by 0.04% following a unit increase in the importance of a failure. Firms in our sample filed for approximately 2 fewer patents and received 6 more citations per year for every 10 patents expired. Likewise, for an increase of 100 citations for expired patents, firms produced almost 2 fewer patents, and citations to their patents increased by 8 per year.

**Toward a Multilevel Model of Learning from Failure**

In order to better understand why an increase in small failures lead to an increase in the quality of R&D (citations) but a decline in R&D output (number of patents), we followed up with some interviews with individuals in the pharmaceutical industry. Specifically, we conducted informal interviews with patent attorneys in pharmaceutical firms as well as in-depth interviews with four scientists who have worked with and patented in the organizations in our sample. The interviews were unstructured but all featured the following open-ended questions: “What drives firm patenting behavior?” “In your opinion, why do firms give up patents?” “Are individual
TABLE 2
Descriptive Statistics and Partial Correlations

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean</th>
<th>SD</th>
<th>Min.</th>
<th>Max.</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. R&amp;D output (log)</td>
<td>3.31</td>
<td>1.55</td>
<td>0.00</td>
<td>7.09</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. R&amp;D output quality (log)</td>
<td>4.36</td>
<td>2.01</td>
<td>0.00</td>
<td>9.46</td>
<td>−0.00</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Failures (total)</td>
<td>45.67</td>
<td>77.05</td>
<td>1.00</td>
<td>1076</td>
<td>0.08</td>
<td>0.01</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Failures after 4 years</td>
<td>16.37</td>
<td>25.16</td>
<td>1.00</td>
<td>180</td>
<td>−0.11</td>
<td>−0.02</td>
<td>0.87</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Failures after 8 years</td>
<td>22.17</td>
<td>37.16</td>
<td>1.00</td>
<td>544</td>
<td>−0.11</td>
<td>−0.05</td>
<td>0.77</td>
<td>0.36</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Failures after 12 years</td>
<td>17.65</td>
<td>29.37</td>
<td>1.00</td>
<td>368</td>
<td>0.12</td>
<td>0.06</td>
<td>0.57</td>
<td>−0.01</td>
<td>0.68</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Importance of failures</td>
<td>303</td>
<td>687</td>
<td>0.00</td>
<td>8428</td>
<td>−0.16</td>
<td>0.43</td>
<td>−0.10</td>
<td>−0.07</td>
<td>0.32</td>
<td>0.64</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Number of alliances</td>
<td>2.82</td>
<td>4.80</td>
<td>0.00</td>
<td>40</td>
<td>−0.07</td>
<td>0.10</td>
<td>0.05</td>
<td>0.07</td>
<td>0.01</td>
<td>−0.18</td>
<td>−0.00</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. R&amp;D unit size</td>
<td>248</td>
<td>389</td>
<td>1.67</td>
<td>2835</td>
<td>0.05</td>
<td>0.11</td>
<td>0.44</td>
<td>0.46</td>
<td>0.19</td>
<td>−0.05</td>
<td>0.33</td>
<td>0.19</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Number of countries</td>
<td>3.56</td>
<td>2.67</td>
<td>1.00</td>
<td>13.67</td>
<td>0.41</td>
<td>0.29</td>
<td>0.26</td>
<td>0.22</td>
<td>−0.06</td>
<td>0.02</td>
<td>0.08</td>
<td>0.30</td>
<td>0.07</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Technological focus</td>
<td>0.24</td>
<td>0.22</td>
<td>0.03</td>
<td>1.00</td>
<td>−0.13</td>
<td>−0.09</td>
<td>−0.05</td>
<td>−0.05</td>
<td>−0.16</td>
<td>−0.12</td>
<td>−0.01</td>
<td>−0.09</td>
<td>−0.04</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Number of litigations</td>
<td>4.41</td>
<td>7.15</td>
<td>0</td>
<td>52</td>
<td>0.03</td>
<td>0.19</td>
<td>0.04</td>
<td>−0.04</td>
<td>0.03</td>
<td>0.20</td>
<td>0.15</td>
<td>0.20</td>
<td>0.01</td>
<td>0.17</td>
<td>0.37</td>
<td>1</td>
</tr>
</tbody>
</table>
TABLE 3
Arellano–Bond Model Estimates for R&D Output\

<table>
<thead>
<tr>
<th>Variable</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
<th>Model 5</th>
<th>Model 6</th>
<th>Model 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D output_{t - 1} (log)</td>
<td>0.48*** (0.06)</td>
<td>0.54*** (0.06)</td>
<td>0.78*** (0.09)</td>
<td>0.44*** (0.05)</td>
<td>0.68*** (0.08)</td>
<td>0.80*** (0.10)</td>
<td>0.72*** (0.10)</td>
</tr>
<tr>
<td>Failures (total)</td>
<td>-0.005*** (0.00)</td>
<td>-0.002* (0.000)</td>
<td>-0.005*** (0.000)</td>
<td>-0.002** (0.00)</td>
<td>-0.002** (0.000)</td>
<td>-0.003*** (0.000)</td>
<td></td>
</tr>
<tr>
<td>Importance of failures</td>
<td>-0.003*** (0.000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failures after 4 years</td>
<td>-0.003 (0.02)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-0.004 (0.003)</td>
</tr>
<tr>
<td>Failures after 8 years</td>
<td></td>
<td>-0.007*** (0.00)</td>
<td></td>
<td></td>
<td></td>
<td>-0.01*** (0.00)</td>
<td></td>
</tr>
<tr>
<td>Failures after 12 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.01 (0.004)</td>
</tr>
<tr>
<td>Number of alliances</td>
<td>-0.10*** (0.01)</td>
<td>-0.06*** (0.01)</td>
<td>-0.04*** (0.01)</td>
<td>-0.04*** (0.01)</td>
<td>-0.06*** (0.01)</td>
<td>-0.06*** (0.01)</td>
<td>-0.05*** (0.01)</td>
</tr>
<tr>
<td>R&amp;D unit size</td>
<td>0.002*** (0.00)</td>
<td>0.001*** (0.00)</td>
<td>0.001*** (0.00)</td>
<td>0.001*** (0.00)</td>
<td>0.001*** (0.00)</td>
<td>0.001*** (0.00)</td>
<td>0.001*** (0.00)</td>
</tr>
<tr>
<td>Number of countries</td>
<td>0.22*** (0.03)</td>
<td>0.23*** (0.03)</td>
<td>0.24*** (0.03)</td>
<td>0.28*** (0.03)</td>
<td>0.25*** (0.03)</td>
<td>0.27*** (0.04)</td>
<td>0.30*** (0.04)</td>
</tr>
<tr>
<td>Technological focus</td>
<td>0.24† (0.12)</td>
<td>-0.04 (0.16)</td>
<td>-0.02 (0.18)</td>
<td>0.06 (0.15)</td>
<td>-0.12 (0.20)</td>
<td>-0.15 (0.39)</td>
<td>-2.10** (0.65)</td>
</tr>
<tr>
<td>Number of litigations</td>
<td>-0.01 (0.00)</td>
<td>-0.00 (0.00)</td>
<td>-0.00 (0.00)</td>
<td>-0.00 (0.00)</td>
<td>0.00 (0.00)</td>
<td>-0.00 (0.01)</td>
<td>-0.00 (0.01)</td>
</tr>
<tr>
<td>Constant</td>
<td>-0.32* (0.15)</td>
<td>-0.26 (0.17)</td>
<td>-0.44† (0.23)</td>
<td>-0.40** (0.16)</td>
<td>-0.38 (0.22)</td>
<td>-1.05*** (0.30)</td>
<td>-1.44*** (0.33)</td>
</tr>
<tr>
<td>Number of instruments</td>
<td>239</td>
<td>269</td>
<td>126</td>
<td>300</td>
<td>143</td>
<td>103</td>
<td>115</td>
</tr>
<tr>
<td>Number of observations</td>
<td>1003</td>
<td>859</td>
<td>849</td>
<td>868</td>
<td>753</td>
<td>498</td>
<td>447</td>
</tr>
<tr>
<td>Number of groups</td>
<td>90</td>
<td>83</td>
<td>81</td>
<td>81</td>
<td>81</td>
<td>74</td>
<td>71</td>
</tr>
<tr>
<td>Wald χ²</td>
<td>1177</td>
<td>1138</td>
<td>973</td>
<td>1210</td>
<td>1016</td>
<td>835</td>
<td>876</td>
</tr>
<tr>
<td>χ²</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.0000</td>
</tr>
</tbody>
</table>

*a Numbers of observations are different across different models because of the difference in the number of observations for expired patents after 4, 8, and 12 years. For example, patents that expired after 4 years first appeared in the year 1985 whereas patents that expired after 8 years first made it into our dataset in the year 1989, leading to lower number of observations. Following the same logic, number of observations in models with the variable “failures after 12 years” is even fewer.

b Standard errors in parentheses.

corresponding p values: * p < 0.10, ** p < 0.05, *** p < 0.01, **** p < 0.001
### Table 4

Arellano–Bond Model Estimates for R&D Output Quality<sup>a,b</sup>

<table>
<thead>
<tr>
<th>Variable</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
<th>Model 5</th>
<th>Model 6</th>
<th>Model 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D output quality&lt;sub&gt;t−1&lt;/sub&gt;</td>
<td>0.60*** (0.03)</td>
<td>0.44*** (0.04)</td>
<td>0.36*** (0.04)</td>
<td>0.37*** (0.04)</td>
<td>0.59*** (0.04)</td>
<td>0.25*** (0.05)</td>
<td>0.20*** (0.05)</td>
</tr>
<tr>
<td>(log)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failures (total)</td>
<td>0.007*** (0.00)</td>
<td>0.003** (0.00)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Importance of failures</td>
<td>0.005*** (0.00)</td>
<td>0.006*** (0.00)</td>
<td>0.002** (0.00)</td>
<td>0.004*** (0.00)</td>
<td>0.004*** (0.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failures after 4 years</td>
<td>0.01** (0.00)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failures after 8 years</td>
<td>0.005* (0.002)</td>
<td>-0.007** (0.00)</td>
<td></td>
<td>0.004† (0.002)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failures after 12 years</td>
<td></td>
<td>-0.002 (0.002)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of alliances</td>
<td>0.05*** (0.01)</td>
<td>0.05*** (0.01)</td>
<td>0.04** (0.01)</td>
<td>0.04** (0.01)</td>
<td>0.04*** (0.01)</td>
<td>0.04*** (0.01)</td>
<td>0.02* (0.01)</td>
</tr>
<tr>
<td>R&amp;D unit size</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
<td>0.001*** (0.00)</td>
<td>0.001*** (0.00)</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
<td>0.00 (0.00)</td>
</tr>
<tr>
<td>Number of countries</td>
<td>0.01 (0.03)</td>
<td>-0.00 (0.03)</td>
<td>-0.03 (0.03)</td>
<td>-0.03 (0.03)</td>
<td>0.00 (0.02)</td>
<td>-0.03 (0.03)</td>
<td>-0.04 (0.03)</td>
</tr>
<tr>
<td>Technological focus</td>
<td>-0.52* (0.20)</td>
<td>-0.52* (0.24)</td>
<td>-0.59** (0.22)</td>
<td>-0.61** (0.21)</td>
<td>-0.36 (0.17)</td>
<td>-0.42 (0.30)</td>
<td>-0.18* (0.49)</td>
</tr>
<tr>
<td>Number of litigations</td>
<td>0.01† (0.00)</td>
<td>0.01† (0.00)</td>
<td>0.01† (0.00)</td>
<td>0.01† (0.00)</td>
<td>0.01† (0.00)</td>
<td>0.00 (0.00)</td>
<td>0.01† (0.00)</td>
</tr>
<tr>
<td>Constant</td>
<td>1.76*** (0.19)</td>
<td>2.29*** (0.20)</td>
<td>2.69*** (0.20)</td>
<td>2.59*** (0.21)</td>
<td>2.11*** (0.25)</td>
<td>4.28*** (0.31)</td>
<td>4.58*** (0.32)</td>
</tr>
<tr>
<td>Number of instruments</td>
<td>172</td>
<td>188</td>
<td>204</td>
<td>204</td>
<td>103</td>
<td>211</td>
<td>270</td>
</tr>
<tr>
<td>Number of observations</td>
<td>936</td>
<td>813</td>
<td>805</td>
<td>822</td>
<td>778</td>
<td>500</td>
<td>451</td>
</tr>
<tr>
<td>Number of groups</td>
<td>86</td>
<td>82</td>
<td>80</td>
<td>81</td>
<td>82</td>
<td>73</td>
<td>71</td>
</tr>
<tr>
<td>Wald $\chi^2$</td>
<td>780</td>
<td>853</td>
<td>943</td>
<td>936</td>
<td>915</td>
<td>178</td>
<td>180</td>
</tr>
<tr>
<td>$\chi^2$</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.0000</td>
</tr>
</tbody>
</table>

<sup>a</sup> Numbers of observations are different across different models because of the difference in the number of observations for expired patents after 4, 8, and 12 years. For example, patents that expired after 4 years first appeared in the year 1985, whereas patents that expired after 8 years first made it into our dataset in the year 1989, leading to lower number of observations. Following the same logic, number of observations in models with the variable “failures after 12 years” is even fewer.

<sup>b</sup> Standard errors in parentheses.

* $p < 0.1$

** $p < 0.05$

*** $p < 0.01$

**** $p < 0.00$
scientists aware that firms have not renewed their patents, and how do they react to such information?” We refrained from asking leading questions that would either support or negate our hypotheses. Below are some conclusions drawn from our interviews.

First, decisions to file and renew patents are made at the firm level, through the intellectual property (IP) office. With respect to patent applications, all interviewees confirmed what prior research had documented. IP is critical for competitive advantage, and firms develop specific IP strategies to protect the drugs that they hope to launch in the market. Scientists are asked to file disclosures with the IP office as soon as they have reached a milestone in their work. This could be a new molecule, a new mechanism, or a new application. The IP office makes decisions as to whether the firm will file for a patent or not. The decision to file for a patent in large, established firms is never made by the individual scientist.

Similarly, the decision to renew (or not) a patent is also made by the firm’s IP office. Typically such decisions are based on a multitude of factors that include but are not limited to the performance of the R&D program/laboratory from which the patent originates (this can include failure in field trials, additional patents that negate earlier work, and patents from competitors that negate the work done by the firm) and balancing of the overall IP portfolio in line with its corporate strategy. It is the patent attorneys who compile and distill the knowledge from failed patents and redirect the firm’s patent portfolio. One interviewee suggested that one of the many responsibilities of a patent counsel is to look for commonalities between failed patents and existing patents to see if the existing portfolio can be improved. Interviewees concurred that individual scientists generally do not receive feedback about each discontinued patent, but they do receive information about future research and new technologies from the IP office.

How do non-renewed patents influence the scientists’ work? The interviewees said that the non-renewal of a single patent was not a major decision either for the firm or for the scientist. One of the scientists we interviewed had a patent that was not renewed but he did not seem too concerned about it. That said, the same scientist mentioned that if many patents from the same inventor were not renewed, this would serve as feedback to the inventor. Also, most scientists are not likely to change their short-term behavior based on the non-renewal of their patents; that is, they would continue to turn in the patent disclosures to the IP office even though the firm could choose to reduce filing patents from them. All scientists explained that the IP office worked with respective program/laboratory managers to collect and analyze information, and decide whether particular programs were effective (i.e., create knowledge that could lead to IP that was useful). There was less of an emphasis on telling individual scientists to reduce or increase patent disclosures in particular areas.

Data from these interviews suggest a multilevel perspective of organizational learning in the pharmaceutical industry. The R&D process can be conceived as a two-step process: Patentable ideas are generated in the first step, and these ideas are filtered (at multiple gates) at the second step akin to an innovation tournament (Terwiesch & Ulrich, 2009). While individual scientists are the ones who work on research programs and produce patentable work, it is at the firm level (through the IP office) that these ideas are filtered based on value and place in the corporate R&D portfolio. The accumulated feedback is used to improve the firm’s filters in selecting projects with higher expected returns. Adaptation of the firm’s selection filters occurs relatively quickly, since IP officers constantly analyze past failures, have a clear view of the firm’s overall R&D strategy, and can execute non-renewals relatively easily. In contrast, this knowledge may not immediately influence the generation of patents for several reasons. First, individual scientists may not necessarily possess the knowledge about the overall health and direction of the research portfolio, and where their work stands relative to this portfolio. They may receive feedback from failed patents as a signal to change research direction only after several such failures have accumulated. Second, even when scientists receive such feedback, the path-dependent nature of the search process (e.g., Levinthal & March, 1993; March & Simon, 1958; Nelson & Winter, 1982) is likely to lead them to continue working on what they did before. As put by one of our interviewees, “a general manager wants his scientists to start working on new technologies more often than scientists are willing to.” In other words, starting a brand new research agenda takes time. Third, scientists’ personal motives and incentives may cause them to receive the feedback in an unfavorable way. Prior work suggests that scientists value independence and intrinsic rewards, and their output is highly correlated with the perceived importance and value of their work (e.g., Sauermann & Cohen, 2010). A concern
with job security may cause threat–rigidity responses (Staw, Sandelands, & Dutton, 1981) and reduce output (Sauermann & Cohen, 2010). Feedback about non-renewals may therefore cause scientists to struggle with output.

In sum, the multilevel process of learning in the R&D process operates as follows. While the selection mechanism operates at the firm level and adapts to negative feedback relatively promptly through non-renewals, the idea-generation mechanism operates at the individual scientist level and is slower to adapt to negative feedback. As a result, while IP officers are able to influence the overall quality of the R&D portfolio through non-renewals, they have little influence on the generation of new ideas. The lag in transferring knowledge to scientists, combined with the path-dependent nature of search and scientists’ motives, cause a dip in the R&D output as individual scientists slowly adapt to incoming feedback.

An examination of the lag structure for our two dependent variables is consistent with this model. In supplementary analyses of different lag structures, we found that the decline in R&D output was more immediate, but the impact on R&D output quality was more gradual. This suggests that selection processes adapt to feedback from failures more promptly, causing a decline in the number of patents, followed by an increase in R&D output quality. Idea generation follows with a lag, and thus fails to compensate for the decline in R&D output in the short run.

Alternative Explanations and Robustness

We conducted several tests in order to rule out alternative explanations. A first potential explanation is that our results are due to the risk preferences of the organizational decision makers and not due to learning. Theory suggests two possible ways in which firms’ risk preferences may influence their responses to failure. On the one hand, performance feedback theory suggests that firms are likely to become more risk seeking following a deviation from their aspiration level (Cyert & March, 1963; Greve, 2003). On the other hand, firms may move away from riskier projects by increasing their risk threshold due to the “hot-stove effect” (Denrell & March, 2001). In order to see if firms changed their criteria for project choice in response to failure, we examined whether and how small failures at time \( t - 1 \) influenced the total number of subclasses and number of novel subclasses in which the firms patented at time \( t \). The total numbers of subclasses and novel subclasses represent the breadth of the firm’s search, and have been used as measures of technological uncertainty involved in the search process as well as of the level of technological exploration (Fleming, 2001; Rosenkopf & Nerkar, 2001). The results show no significant relationship between the number of total subclasses or novel subclasses and number of failures, providing preliminary evidence that firms do not become significantly more or less risk seeking in their project choice in response to failure.

A second alternative explanation is that, even though we observe premature patent expirations as small failures, they may in fact be components of a larger, systemic failure, such as a failure of a research agenda or a drug that is already in the market. As explained above, we controlled for both the number of litigations involving the firm and the technological focus of the failed patents to rule out this possibility. According to Tables 3 and 4, the former variable was not significant in either model, while the latter was negatively significant in both the R&D output and quality models, suggesting that firms might struggle in R&D activities when failures are more concentrated in certain research areas. Still, these controls did not influence our core results that past failures decreased R&D output and increased R&D output quality.

Next, we address the alternative explanation that not all patent expirations are failures, and not all continuations are successes. Firms may renew patents for competitive or legal reasons, such as fending off a threat of litigation or for cross-licensing. We find it unlikely that such alternative explanations will systematically bias our results for several reasons. First, competitive and legal uses of patents in the pharmaceutical industry are limited compared to other industries such as electronics or computers (Hall, Helmers, von Graevenitz, & Rosazza-Bondibene, 2013; Lehman, 2003). Second, our conversations with patent attorneys in pharmaceutical firms supported the notion of failed patents as a vehicle for learning in a way consistent with our results. Third, we did not find any support for such uses in our empirical design, since number of litigations was not significant or weakly significant in our models. Finally, the noise in our measure of failure is likely to reduce the strength of our results, making our estimates conservative.

Another alternative explanation is that firms may learn from the experiences of all other firms, not just their own. This would suggest a different mechanism of vicarious learning rather than the one we put forth.
In unreported models, we controlled for the number, importance, and timing of failures of all firms in the industry other than the focal firm. These population-level controls revealed some interesting patterns. For instance, the total number of failures at the population level is associated with a drop in the firm’s R&D output, but does not significantly affect the firm’s R&D output quality, possibly suggesting that firms may find it harder to learn from other firms’ failures. At the same time, these controls did not significantly change our results, ruling out population-level learning as an alternative explanation.

We also tested whether learning from failures in our context is cumulative in nature. Since previous values of the variables are used as instruments to estimate current values of both the dependent and the independent variables in the Arellano–Bond model, using cumulative measures can potentially lead to overestimation of the contribution of the previous periods. Instead, we used the cumulative measure of our independent variables with an annual forgetting factor of 0.8 in the fixed effects negative binomial model (Darr, Argote, & Epplle, 1995). The results are consistent with those of the previous models.

As we only observed discontinuations at the legally determined 4, 8 and 12 years, we may be missing the time at which discontinuation decisions are actually made. For instance, it is possible that a molecule associated with a patent fails at most four years earlier than we observe it in our data. In order to take into account this possibility, we assumed that the discontinuation decisions were made at an average of two years before we observed them, and used independent variables from $t - 2$ to test our hypotheses. This test led to fewer observations but the results were robust.

We also tested for the presence of curvilinearity in our models. Although we find no support for a curvilinear relationship between the number and importance of failures and R&D output, we do find the presence of a curvilinear relationship between number and importance of failures and R&D output quality. However, the inflection point of the curve is estimated to be at 5,263 patent expirations, well beyond the maximum of 1,076 patent expirations observed in our sample. We also repeated our models with negative binomial regression models with firm fixed effects (Hausman, Hall, & Griliches, 1984; Henderson & Cockburn, 1994), and found that the results are similar to those from previous specifications.

In short, the empirical patterns that we observed in the data, the supplementary evidence ruling out alternative mechanisms, and the qualitative evidence combined suggest that our results reflect learning processes, and that learning from failure in pharmaceutical firms is a multilevel process. Project-selection mechanisms at the firm level adapt to feedback from failed patents faster than generation mechanisms at the individual scientist level, causing us to observe an increase in R&D output quality and a decline in R&D output.

**DISCUSSION AND CONCLUSION**

Previous research on learning from past experience, including failures, has argued that experience in general leads to higher productivity and lower unit cost in manufacturing and service industries (Argote, 1996; Argote & Epplle 1990). However, results obtained in the current study tell a different story. Specifically, we found that, as the number of failures increases, R&D output, measured as the number of patents filed by the firm, decreases, whereas the quality of the patents, measured as citation to those patents, increases. Similarly, the importance and timing of small failures cause opposing changes in R&D output and R&D output quality. This difference in the effect of number, timing, and importance of failures on R&D output and quality points to the potentially different drivers of these two dimensions of R&D performance.

We offered a potential reconciliation of our results based on our interviews with industry participants. As opposed to many studies that depict organizations as monolithic entities, our interviews suggest a multilevel model of learning, in line with process models of resource allocation (Bower, 1970; Burgelman, 1983, 1991; Noda & Bower, 1996; see Gaba & Joseph, 2013, for a consideration of divergent aspiration levels at multiple levels). To reiterate, we suggest that patent generation occurs at the individual scientist level, whereas patent selection for the overall portfolio takes place at the level of the IP office. While the selection mechanisms adjust more easily to feedback from failed projects, the idea-generation process adjusts more slowly, due to the lag in relaying feedback to individual scientists, the path dependency of search processes, and the motives of individual scientists. As a result, fast adaptation of selection leads to higher-quality patents, whereas slow adaptation of generation leads to an immediate drop in R&D output.
We contribute to the organizational learning literature in the following ways. First, our study confirms the critical role of failures for organizational performance and adds to prior studies by examining small failures in experimentation—an understudied but important type of failure (e.g., Sitkin, 1992). We show in this paper how such failures can provide firms with critical feedback in exploration. Data presented in Figure 1 suggest that learning from failures did not reduce the number of subsequent failures in our study, as opposed to the patterns in other types of failures covered in prior research (e.g., Haunschild & Rhee, 2004; Haunschild & Sullivan, 2002; Madsen & Desai, 2010). This may suggest that firms do not use small failures to increase the reliability of their processes but to expand their search and identify new directions. This interesting observation underscores the unique nature of small failures in experimentation and the importance of studying them separately from other failures.

In addition, our finding that small failures lead to a decrease in R&D output but an increase in quality is a novel contribution to the literature on innovation. While prior studies on R&D outcomes have examined different factors influencing R&D outcomes, the role of prior failures has so far been neglected. Our findings on the timing and importance of small failures also provide novel insights on how firms learn from failures in the context of innovation and add to the understanding of the innovation process.

We believe there are certain boundary conditions for these findings. For instance, firms in the pharmaceutical industry are faced with extreme uncertainty and long development times. The outcomes of the R&D process are highly skewed, with few projects generating most of the returns. The abundance of generated ideas and the need to filter them necessitate the separation of idea-generation and selection processes. Our results are likely to hold in other innovative industries with similar characteristics, such as venture capital, corporate venturing, or creative endeavors such as film production. Future studies can examine to what extent these results are generalizable to other R&D-intensive industries. Do firms in different industries perceive patents differently in terms of their value? Do such firms vary in how they learn from such failures? These are some of the questions to be explored to broaden the understanding of learning from small failures in the context of innovation.

Our findings also have implications for practicing R&D managers. While the study by no means recommends failures, it encourages experimentation and conscious attention to evaluation of patents as early as possible. Higher rate of experimentation will increase the number of failures but also the likelihood of finding the right bet. Similarly, our findings suggest that firms should try to remove subpar projects from their portfolio as early as possible, and not be afraid to eliminate important projects from the portfolios.

Despite its contributions, the study has several limitations. First, we could not observe the underlying reasons for patent failures or discriminate between these underlying reasons as determinants of learning. We leave it to future studies to disentangle the relationships between different reasons for patent expirations and the subsequent learning outcomes. At the same time, the process by which these failures lead to improvements in R&D performance also goes unobserved. While we believe that the improvements are both in ongoing projects as well as in the reallocation of R&D resources, we did not distinguish between these two mechanisms and their relative importance in this study. Future studies can greatly enhance our understanding of underlying mechanisms governing learning from failures. Last, future studies could provide more robust analysis of the multilevel model of learning at the idea-generation and selection steps.

It is worth noting that patent expirations represent a distinct type of failure in the pharmaceutical R&D process. By studying all patents, as opposed to those that failed in clinical trials, we are able to get a more complete picture of small failures in experimentation. It is also possible that some ideas fail even before reaching the patenting stage. Given the high rate of patenting in the pharmaceutical industry, these early ideas probably show little promise to begin with. Future studies may find it fruitful to compare these different kinds of failures in terms of learning outcomes.

**REFERENCES**


Jaffe, A. B. 1986. Technological opportunity and spillovers of R&D: Evidence from firms’ patents, profits and


Rajat Khanna (rkhanna@tulane.edu) is an assistant professor in the Management Department of the Freeman School of Business at Tulane University. His research focuses on understanding how technological failures and search processes affect innovation within firms. He received his PhD from the University of North Carolina at Chapel Hill and his undergraduate degree from the Indian Institute of Technology Delhi.

Isin Guler (isinguler@sabanciuniv.edu) is an associate professor of strategy at Sabanci University’s School of Management in Turkey. Her current research interests are in the areas of innovation strategy and venture capital. She received her PhD from the Wharton School of the University of Pennsylvania.

Atul Nerkar (atul_nerkar@unc.edu) is the Jeffrey A Allred Distinguished Scholar and professor of strategy and entrepreneurship at the Kenan–Flagler Business School at the University of North Carolina at Chapel Hill. His research interests are in the areas of technology, innovation, and entrepreneurship. Atul has a PhD in strategy from the Wharton School of the University of Pennsylvania.
Copyright of Academy of Management Journal is the property of Academy of Management and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.